Cystic Fibrosis Transmembrane Conductance Regulator
Links shared publicly online about this topic
Disrupted posttranscriptional regulation of the cystic fibrosis transmembrane conductance regulator (CFTR) by a 5′UTR mutation is associated with a cftr-related disease - Lukowski - 2011 - Human Mutation - Wiley Online Library
onlinelibrary.wiley.com — “Disrupted posttranscriptional regulation of the cystic fibrosis transmembrane conductance regulator (CFTR) by a 5′UTR mutation is associated with a cftr-related disease - Lukowski - 2011 - Human Mutation - Wiley Online Library” View full resource at onlinelibrary.wiley.com
Most Recently Shared on September 20, 2011 at 4:24 am By:
Disrupted posttranscriptional regulation of the cystic fibrosis transmembrane conductance regulator (CFTR) by a ... http://t.co/tiutnBdE
Link Between Smoking Cigarettes And Cystic Fibrosis
medicalnewstoday.com — “New research in The FASEB Journal suggests that cigarette smoke interferes with the Cystic Fibrosis Transmembrane Conductance Regulator protein, leading to dry, sticky mucus and increased i” View full resource at medicalnewstoday.com
Most Recently Shared on October 14, 2011 at 7:05 am By:
MNT Cystic Fibrosis Health News
Link Between Smoking Cigarettes And Cystic Fibrosis http://t.co/0R388jiS #cysticfibrosis
Cystic Fibrosis: Unraveling A New Regulator
medicalnewstoday.com — “Cystic fibrosis (CF), a chronic disease that clogs the lungs and leads to life-threatening lung infections, is caused by a genetic defect in a chloride channel called cystic fibrosis transmembrane” View full resource at medicalnewstoday.com
Most Recently Shared on September 21, 2011 at 7:05 am By:
MNT Cystic Fibrosis Health News
Cystic Fibrosis: Unraveling A New Regulator http://mnt.to/3ZLD #cysticfibrosis
Infliximab Successfully Treats Cystic Fibrosis And Crohn's Disease
medicalnewstoday.com — “Cystic fibrosis (CF) is the most common life-threatening autosomal recessive disease in Caucasian children; it has an incidence of 1 case in every 2500 children born alive. CF involves an anomalou” View full resource at medicalnewstoday.com
Most Recently Shared on April 20, 2010 at 5:12 pm By:
Infliximab Successfully Treats Cystic Fibrosis And Crohn's Disease http://mnt.to/3Bv5 #crohns #ibd
FDA approves Kalydeco to treat rare form of cystic fibrosis
fda.gov — “The U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.” View full resource at fda.gov
Most Recently Shared on January 31, 2012 at 4:18 pm By:
Scott Hensley Health Organization
FDA approves Kalydeco to treat rare form of cystic fibrosis http://t.co/KfefwJ6S $VRTX Price? ~$250K/yr says @MarkSchoenebaum
Protein Involved In Cystic Fibrosis Also Plays Role In Emphysema, Chronic Lung Disease - QualityPoint Technologies
qualitypointtech.net — “A team of Johns Hopkins Children's Center researchers has discovered that a protein involved in cystic fibrosis (CF) also regulates inflammation and cell death in emphysema and may be responsible for other chronic lung diseases. The findings, published online in the December issue of The Journal of Immunology, pave the way toward new treatments to prevent lung damage caused by infections or cigarette smoke in emphysema. The protein, called CFTR (cystic fibrosis transmembrane conductance regulato” View full resource at qualitypointtech.net
Most Recently Shared on December 31, 2010 at 8:45 am By:
Protein Involved In Cystic Fibrosis Also Plays Role In Emphysema, Chronic Lung Disease: A team of Johns Hopkins Ch... http://bit.ly/gn3Iws
Dying Young | Science | guardian.co.uk
guardian.co.uk — “These short documentary videos explore the struggles of living with cystic fibrosis and the current state of research into this illness” View full resource at guardian.co.uk
Most Recently Shared on December 15, 2010 at 11:58 am By:
Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals
news-medical.net — “Napo Pharmaceuticals, Inc. has in-licensed from the University of California Regents additional small-molecule cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor technology including gastrointestinal (GI) and polycystic kidney disease (PKD) indications.” View full resource at news-medical.net
Most Recently Shared on October 26, 2009 at 4:54 pm By:
HIV/AIDS News: Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals: Napo Pharma.. http://bit.ly/tikie
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Genetics OW
Organizing genetics resources shared by health experts, advocates, and organizations into WisdomCards.
-
MNT Cystic Fibrosis
The latest cystic fibrosis news published daily. Articles from research centers, universities and prestigious journals.
-
MNT Cystic Fibrosis
The latest cystic fibrosis news published daily. Articles from research centers, universities and prestigious journals.
Advertisement
